Pacemaker Biocompatible & Battery Materials Patent Landscape
Medtronic holds the dominant position in pacemaker biocompatible and battery materials, commanding a commanding lead over a concentrated tier of cardiac-device incumbents, with electrotherapy applications accounting for the overwhelming share of technical activity. Annual filing volume peaked in 2017 and has eased since, signalling a maturing field where adjacent branches in implant coatings and nanotechnology remain comparatively sparse.
Medtronic leads a concentrated incumbent field
Medtronic holds the top position with 115 patent records, more than double the second-ranked Pacesetter (55 patent records) and nearly three times Boston Scientific Neuromodulation (40 patent records). The top five filers together account for 45% of the combined output of the hundred largest filers in this space.
The field is sharply tiered: a cluster of four established cardiac-device companies — Medtronic, Pacesetter, Boston Scientific Neuromodulation, and Intermedics — account for the bulk of ranked activity, with a long tail of smaller filers, academic institutions, and individual inventors below them.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic, Inc. | 115 | |
| 2 | Pacesetter, Inc. | 55 | |
| 3 | Boston Scientific Neuromodulation Corporation | 40 | |
| 4 | Intermedics, Inc. | 35 | |
| 5 | Advanced Neuromodulation Systems, Inc. | 23 | |
| 6 | Cardiac Pacemakers, Inc. | 19 | |
| 7 | Pressure Products Medical Supplies, Inc. | 15 | |
| 8 | St. Jude Medical AB | 14 | |
| 9 | Telectronics | 11 | |
| 10 | Augusta University Research Institute, Inc. | 11 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Tsinghua University | 10 | |
| 12 | Hon Hai Precision Industry Co., Ltd. (Foxconn) | 10 | |
| 13 | LivaNova USA, Inc. | 10 | |
| 14 | Greatbatch Ltd. | 10 | |
| 15 | Medtronic Vascular Galway | 9 | |
| 16 | Biophan Technologies | 9 | |
| 17 | Virginia Tech Intellectual Properties, Inc. | 8 | |
| 18 | Kurth | 7 | |
| 19 | Nathan Lee Olson | 6 | |
| 20 | Duke University | 6 |
Medtronic’s scale implies deep prior art in core electrotherapy and lead-material design, making direct competition in those sub-areas costly. Challengers seeking freedom to operate are likely better positioned in the lower-density adjacent branches such as implant coatings and nanotechnology.
Patent records filed within the most recent 18–24 months are subject to publication lag and will under-represent true recent activity; trend observations for 2024–2026 should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing activity eased from a 2017 peak; electrotherapy dominates the technology mix
The annual filing trend and technology composition charts together show a field that built rapidly through mid-decade but has since moderated, concentrated almost entirely in electrotherapy-related IPC classes.
Annual filing trend
Filings peaked at 32 records in 2017 and have declined on a multi-year basis (recent-window growth of -12%). Years from 2024 onward reflect publication lag and should not be read as a confirmed sustained trough; the 2023–2025 figures will be restated upward as pending applications publish.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (electrotherapy and radiation therapy) dominates the technology mix by a wide margin, reflecting the core pacemaker stimulation function. A61B (diagnosis and surgery) and A61M (devices for body fluids) form a secondary tier. Battery-specific class H01M and nanotechnology class B82Y each hold minimal shares, identifying areas of relative sparsity.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Controllable, wearable MRI-compatible cardiac pace…
A controllable, wearable MRI-compatible, fixed-rate (VOO) pacemaker includes a self-contained power source and a pulse generator housed at the proximal end of a photonic catheter in a first enclosure designed to operate externally of a patient’s body. Electrical pulses output by the pulse generator are converted into light energy and directed into the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Non-linear electrode array | 679 |
| 2 | Telescopic introducer with a compound curvature fo… | 524 |
| 3 | Apparatus for directionally stimulating nerve tissue | 442 |
| 4 | Single preformed catheter configuration for a dual… | 356 |
| 5 | Apparatus and methods for applying neural stimulat… | 347 |
| 6 | Epicardial lead for minimally invasive implantation | 325 |
| 7 | System and method for providing electrical and/or … | 311 |
| 8 | Laser extractor for an implanted object | 301 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
The combination of lifecycle stage, applicant concentration, collaboration signals, and geographic spread provides a clear strategic read for teams evaluating entry or expansion in this space.
Decline phase from a 2017 peak
The lifecycle evidence places this field in decline, with annual filing volume easing back from its 2017 peak and a recent-window growth rate of –12%. For R&D teams, this signals that core biocompatible and battery material concepts are heavily documented and incremental improvements face dense prior art. Investment is most defensible in under-served sub-areas where the prior art density is still low.
Lifecycle: DeclineTop five filers hold nearly half the ranked output
The top five filers — Medtronic, Pacesetter, Boston Scientific Neuromodulation, Intermedics, and Advanced Neuromodulation Systems — represent 45% of the hundred largest filers’ combined patent records. This concentration means that new entrants face a high bar in the dominant A61N electrotherapy branch. The long tail of smaller filers and individual inventors below the top tier suggests room for niche specialisation, particularly in materials science sub-classes.
High concentrationBoston Scientific Neuromodulation and Augusta University Research Institute are the most active co-filers
The most active co-filing pair is Boston Scientific Neuromodulation and Augusta University Research Institute, with 11 joint filings, indicating a substantive industry-academia collaboration in this domain. Greatbatch and Galvani Bioelectronics share 3 joint filings, suggesting a secondary industry-to-industry collaboration track. These partnerships represent potential licensing or partnership reference points for new entrants seeking validated R&D channels.
Industry-academia linksUnited States is the dominant filing jurisdiction
The United States leads patent protection by a wide margin, followed by Europe (EPO) and WIPO (PCT). Australia and Canada form a secondary tier. Japan, the United Kingdom, and Germany hold modest positions. The low coverage in India and select European national offices suggests that protection outside the US-EPO-PCT axis is sparse, which may present freedom-to-operate opportunities in those markets for later entrants.
US-centric protectionGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Boston Scientific Neuromodulation Corporation | Augusta University Research Institute, Inc. | 11 |
| Greatbatch Ltd. | Galvani Bioelectronics Ltd. | 3 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic anchors the field; Boston Scientific Neuromodulation is a rising challenger
Two applicant profiles illustrate the contrast between the entrenched incumbent and a newer high-momentum filer. Both are concentrated in A61N electrotherapy, but their trajectories diverge sharply.
Medtronic
Medtronic holds 115 patent records — the largest position in the field — focused primarily on A61N 1 electrotherapy and radiation therapy, with secondary coverage in A61M 25 (devices for body fluids) and A61B 17 (diagnosis and surgery). Its recent filing count of 2 records reflects either a deliberate strategic slowdown or publication lag on very recent applications; this should be interpreted cautiously. The breadth of its technology coverage across lead design, stimulation, and surgical tools makes it the reference prior-art holder across most sub-areas.
patent records: 115Boston Scientific Neuromodulation
Boston Scientific Neuromodulation holds 40 patent records and carries a ‘new entrant’ momentum signal in the most recent period, with 10 recent filings — the highest recent count among the tracked momentum cohort. Its technology focus is concentrated in A61N 1 electrotherapy. Its active co-filing relationship with Augusta University Research Institute (11 joint filings) suggests an academic pipeline that could accelerate output in adjacent biocompatible and interface-material areas.
patent records: 40| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic, Inc. | 2 | ▲ new entrant |
| Mainstay Medical | 8 | ▲ new entrant |
| Pacesetter, Inc. | 4 | ▼ -79% |
| Boston Scientific Neuromodulation Corporation | 10 | ▲ new entrant |
Under-served branches in implant prosthetics, medicinal coatings, and nanotechnology
Several IPC branches adjacent to the dominant A61N electrotherapy core carry low patent record counts and shares, representing areas of relative sparsity. Whether they constitute viable R&D opportunities depends on technical fit and commercial relevance.
B82Y · Nanotechnology applications
With only 8 patent records and a 1% share of the technology composition, B82Y nanotechnology applications is among the sparsest branches in scope. Nanomaterial coatings and nanostructured electrode interfaces are technically relevant to pacemaker biocompatibility — improving charge-transfer efficiency and reducing inflammatory response at the electrode-tissue boundary. The low prior art density and growing general interest in nanomedicine suggest this could be a defensible entry point for teams with nanomaterial synthesis or surface engineering expertise, though commercial pathways in a declining overall field would require validation.
Search this in Eureka →A61L · Sterilising & disinfecting (surface treatment & biocompatibility)
A61L holds 10 patent records and a 1% share, indicating that sterilisation chemistry and surface biocompatibility treatments for implantable pacemaker components are under-documented relative to the electrotherapy core. Antimicrobial and anti-biofouling coatings are directly relevant to long-term device performance and patient safety. This branch is adjacent to the more populated A61F implants class and could benefit from cross-disciplinary work combining polymer chemistry (C08L, also sparse at 1 record) with implant design. Entry here is observationally sparse but would require careful freedom-to-operate analysis given the established players in adjacent implant classes.
Search this in Eureka →Frequently asked questions
The corpus covers 169 patent families in the pacemaker biocompatible and battery materials domain. The applicant ranking and technology composition charts are drawn from patent records, which can exceed the family count because a single family may be filed across multiple jurisdictions.
Medtronic holds the largest position with 115 patent records, ahead of Pacesetter (55 patent records) and Boston Scientific Neuromodulation (40 patent records). The top five applicants together account for 45% of the combined output of the hundred largest filers.
The lifecycle evidence places this field in decline. Annual filing volume peaked in 2017 at 32 records and has eased since, with a recent-window growth rate of -12%. Note that the most recent 18–24 months are subject to publication lag and will be restated as pending applications publish.
The United States leads with 273 patent records, followed by Europe (EPO) at 112 and WIPO (PCT) at 77. Australia and Canada form a secondary tier. Coverage in Japan, the United Kingdom, Germany, India, and Norway is comparatively thin.
Yes. The most active co-filing pair identified is Boston Scientific Neuromodulation and Augusta University Research Institute, with 11 joint filings. Greatbatch and Galvani Bioelectronics share 3 joint filings as a secondary collaboration.
Relative to the dominant A61N electrotherapy class, branches including B82Y nanotechnology applications (8 records, 1% share), A61L sterilising and disinfecting (10 records, 1% share), B05D coating processes (8 records, 1% share), A61K medicinal preparations (14 records, 2% share), and H01M batteries and fuel cells (5 records) are observationally sparse. These represent adjacent areas where prior art density is lower, though commercial opportunity requires separate validation.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.